Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Nurul Annisa; Melisa I Barliana; Prayudi Santoso; Rovina Ruslami

doi:10.3389/fphar.2022.1063413

Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters

Front Pharmacol. 2022 Dec 12:13:1063413. doi: 10.3389/fphar.2022.1063413. eCollection 2022.

Authors

Nurul Annisa^{1

2}, Melisa I Barliana^{1

3}, Prayudi Santoso⁴, Rovina Ruslami⁵

Affiliations

¹ Department of Biological Pharmacy, Biotechnology Pharmacy Laboratory, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
² Unit of Clinical Pharmacy and Community, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia.
³ Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.
⁴ Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran-Hasan Sadikin Hospital, Bandung, Indonesia.
⁵ Division of Pharmacology and Therapy, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

Abstract

Tuberculosis (TB) is an infectious disease that occurs globally. Treatment of TB has been hindered by problems with multidrug-resistant strains (MDR-TB). Fluoroquinolones are one of the main drugs used for the treatment of MDR-TB. The success of therapy can be influenced by genetic factors and their impact on pharmacokinetic parameters. This review was conducted by searching the PubMed database with keywords polymorphism and fluoroquinolones. The presence of gene polymorphisms, including UGT1A1, UGT1A9, SLCO1B1, and ABCB1, can affect fluoroquinolones pharmacokinetic parameters such as area under the curve (AUC), creatinine clearance (C_Cr), maximum plasma concentration (C_max), half-life (t_1/2) and peak time (t_max) of fluoroquinolones.

Keywords: ABCB1; SLCO1B1; UGT1A1; UGT1A9; moxifloxacin; pharmacogenetics; sitafloxacin; trovafloxacin.

Publication types

Review